文献速递流行病学与生物统计

评估阿片使用障碍药物治疗随机对照试验中统计学显著结果的脆弱性:一项系统综述

Assessing fragility of statistically significant findings from randomized controlled trials assessing pharmacological therapies for opioid use disorders: a systematic review.
PubMed 文献 · Trials · 2024-04-27

该系统综述检索6个数据库至2021年9月25日,纳入10项评估阿片替代与拮抗药物治疗阿片使用障碍的随机对照试验,中位样本量82.5例,中位脆弱指数为7.5。作者认为约需8例参与者即可推翻多数试验的结论,并建议未来报告置信区间、脆弱指数并强调结果的临床相关性。

要点

  • 纳入10项随机对照试验,中位样本量82.5例,中位脆弱指数为7.5。
  • 7项研究总体偏倚风险低,2项有一些担忧,1项高。
  • 作者认为约8例参与者即可推翻多数试验的结论。

核心结论

  • 作者认为约8例参与者即可推翻阿片使用障碍领域多数试验的结论。
  • 作者建议未来工作应聚焦于最大化研究报告的透明度,通过报告置信区间、脆弱指数并强调研究结果的临床相关性。

研究设计与样本

  • 系统综述,检索6个数据库从建库至2021年9月25日。
  • 纳入所有平行组或2×2析因设计的随机对照试验,评估任何阿片替代与拮抗药物治疗的有效性,使用二分类主要结局并报告统计学显著结果。
  • 共纳入10项研究,中位样本量为82.5例(四分位距58,179,范围52-226)。
  • 使用Walsh及其同事描述的方法计算每项研究的脆弱指数,并使用修订版Cochrane随机试验偏倚风险工具评估纳入研究的偏倚风险。

主要发现

  • 10项纳入研究的中位脆弱指数为7.5(四分位距4,12,范围1-26)。
  • 总体偏倚风险:7项研究为低,2项研究有一些担忧,1项研究为高。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The fragility index is a statistical measure of the robustness or "stability" of a statistically significant result. It has been adapted to assess the robustness of statistically significant outcomes from randomized controlled trials. By hypothetically switching some non-responders to responders, for instance, this metric measures how many individuals would need to have responded for a statistically significant finding to become non-statistically significant. The purpose of this study is to assess the fragility index of randomized controlled trials evaluating opioid substitution and antagonist therapies for opioid use disorder. This will provide an indication as to the robustness of trials in the field and the confidence that should be placed in the trials' outcomes, potentially identifying ways to improve clinical research in the field. This is especially important as opioid use disorder has become a global epidemic, and the incidence of opioid related fatalities have climbed 500% in the past two decades. METHODS: Six databases were searched from inception to September 25, 2021, for randomized controlled trials evaluating opioid substitution and antagonist therapies for opioid use disorder, and meeting the necessary requirements for fragility index calculation. Specifically, we included all parallel arm or two-by-two factorial design RCTs that assessed the effectiveness of any opioid substitution and antagonist therapies using a binary primary outcome and reported a statistically significant result. The fragility index of each study was calculated using methods described by Walsh and colleagues. The risk of bias of included studies was assessed using the Revised Cochrane Risk of Bias tool for randomized trials. RESULTS: Ten studies with a median sample size of 82.5 (interquartile range (IQR) 58, 179, range 52-226) were eligible for inclusion. Overall risk of bias was deemed to be low in seven studies, have some concerns in two studies, and be high in one study. The median fragility index was 7.5 (IQR 4, 12, range 1-26). CONCLUSIONS: Our results suggest that approximately eight participants are needed to overturn the conclusions of the majority of trials in opioid use disorder. Future work should focus on maximizing transparency in reporting of study results, by reporting confidence intervals, fragility indexes, and emphasizing the clinical relevance of findings. TRIAL REGISTRATION: PROSPERO CRD42013006507. Registered on November 25, 2013.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Naji L, Dennis B, Rodrigues M, et al. Assessing fragility of statistically significant findings from randomized controlled trials assessing pharmacological therapies for opioid use disorders: a systematic review. Trials. 2024. PMID: 38678289. doi:10.1186/s13063-024-08104-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。